


Accepted Manuscript



Validation and Implementation of *BRCA1/2* Variant Screening in Ovarian Tumor Tissue

Marthe M. de Jonge, Dina Ruano, Ronald van Eijk, Nienke van der Stoep, Maartje Nielsen, Juul T. Wijnen, Natalja T. ter Haar, Astrid Baalbergen, Monique E.M.M. Bos, Marjolein J. Kagie, Maaïke P.G. Vreeswijk, Katja N. Gaarenstroom, Judith R. Kroep, Vincent T.H.B.M. Smit, Tjalling Bosse, Tom van Wezel, Christi J. van Asperen

PII: S1525-1578(18)30098-9

DOI: [10.1016/j.jmoldx.2018.05.005](https://doi.org/10.1016/j.jmoldx.2018.05.005)

Reference: JMDI 701

To appear in: *The Journal of Molecular Diagnostics*

Received Date: 6 March 2018

Accepted Date: 1 May 2018

Please cite this article as: de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ, Validation and Implementation of *BRCA1/2* Variant Screening in Ovarian Tumor Tissue, *The Journal of Molecular Diagnostics* (2018), doi: 10.1016/j.jmoldx.2018.05.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Validation and implementation of *BRCA1/2* variant screening in ovarian tumor tissue

Marthe M. de Jonge,* Dina Ruano,* Ronald van Eijk,* Nienke van der Stoep,† Maartje Nielsen,† Juul T.

Wijnen,† Natalja T. ter Haar,* Astrid Baalbergen,‡ Monique E.M.M. Bos,§ Marjolein J. Kagie,¶ Maaïke P.G.

Vreeswijk,|| Katja N. Gaarenstroom,** Judith R. Kroep,†† Vincent T.H.B.M. Smit,* Tjalling Bosse,* Tom van Wezel,* and Christi J. van Asperen†

Footnote: T.v.W. and C.J.v.A. contributed equally.

From the Departments of Pathology* Clinical Genetics,† Human Genetics,|| Gynecology,** and Medical Oncology,†† Leiden University Medical Center, Leiden; the Department of Gynaecology,‡ Reinier de Graaf hospital, Delft; the Department of Medical Oncology,§ Erasmus Medical Center, Rotterdam; and the Department of Gynecology,¶ Haaglanden Medisch Centrum, The Hague, the Netherlands

Corresponding Author:

Tom van Wezel

Albinusdreef 2, 2333 ZA Leiden

E-mail: T.van_Wezel@lumc.nl

Short Title: *BRCA1/2* variant screening in tumor tissue.

Disclosures: Next-generation sequencing was financially supported by AstraZeneca. AstraZeneca had no role in study design, data collection, data analysis, or data interpretation.

Download English Version:

<https://daneshyari.com/en/article/8951981>

Download Persian Version:

<https://daneshyari.com/article/8951981>

[Daneshyari.com](https://daneshyari.com)